サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1363982

EBV（エプスタイン・バールウイルス）診断・治療の世界市場：2023-2030年

Global Epstein-Barr Virus Diagnosis and Treatment Market 2023-2030
出版日: | 発行: Orion Market Research | ページ情報: 英文 198 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
EBV（エプスタイン・バールウイルス）診断・治療の世界市場：2023-2030年
出版日: 2023年09月23日
発行: Orion Market Research
ページ情報: 英文 198 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のEBV（エプスタイン・バールウイルス）診断・治療市場は、予測期間中（2023-2030年）にCAGR 5.1%でかなりの成長が見込まれています。EBVの大規模な蔓延は、その治療に対する需要を生み出し、ひいては世界のEBV診断・治療市場を牽引する重要な要因となっています。EBVはヘルペスウイルスの一種で、感染後は通常、咽頭の上皮組織やリンパ球に生物として存在します。ほとんどのヒトがこのウイルスを保有しており、血液検査ではEBV抗体が低レベルであることが多いです。さらに、多発性硬化症（MS）は不治の自己免疫疾患で、世界中で280万人が罹患しています。全米多発性硬化症協会によれば、MSと診断された人は、中枢神経系に進行性の障害を受け、約7年で寿命を失います。ハーバード大学T.H.チャン公衆衛生大学院の調査チームは、この病気に罹患する最大の危険因子は、EBVに感染したことがあることであると断定しました。

セグメンテーションの展望

世界のEBV診断・治療市場では、抗ウイルス薬が大きなシェアを占めると予想されます。

世界のEBV診断・治療市場において、治療薬の中でも抗ウイルス薬サブセグメントがかなりのシェアを占めると予想されます。抗ウイルス剤は、感染症の場合に投与される最も一般的な薬剤であり、主要な感染症の1つである感染性単核球症は、「モノ (mono)」とも呼ばれる伝染病です。伝染性単核球症の最も一般的な原因はEBVですが、他のウイルスもこの病気を引き起こす可能性があります。伝染性単核球症は10代から20代の若者、特に大学生によく見られます。EBVに感染した10代や若年成人の少なくとも4人に1人が伝染性単核球症を発症します。伝染性単核球症（モノ）やある種のがんの原因として知られるEBVの感染歴は、多発性硬化症（MS）の最も強い危険因子であると考えられています。

地域別の展望

世界のEBV診断・治療市場は、北米（米国、カナダ）、欧州（英国、イタリア、スペイン、ドイツ、フランス、その他欧州地域）、アジア太平洋地域（インド、中国、日本、韓国、その他アジア地域）、世界のその他の地域（中東とアフリカ、ラテンアメリカ）を含む地域別にさらに細分化されています。このうち北米は、世界全体で顕著な市場シェアを占めると予想されています。自己免疫疾患患者の増加とそれに伴う抗体検査需要の増加、また健康保険制度の利点に対する国民の意識を高めるための政府の取り組みなどが、この地域の市場成長を促進すると予想される主な要因のいくつかです。

世界のEBV診断・治療市場は、アジア太平洋地域が大きなCAGRで成長する見込み

全地域の中で、アジア太平洋地域は予測期間中にかなりのCAGRで成長すると予測されています。同地域の成長は、ジェネリック人口の増加と、同地域における新たな疾患の症例増加による臨床試験数の増加に起因しています。2022年5月、米国立衛生研究所（NIH）の一部である米国立アレルギー感染症研究所（NIAID）は、EBVの治験用予防ワクチンを評価する初期段階の臨床試験を開始しました。EBVは伝染性単核球症の主な原因であり、特定のがんや自己免疫疾患と関連しています。この第1相試験は、EBVワクチンの臨床試験としては過去10年間で2つしかない試験のうちの1つです。メリーランド州ベセスダのNIH臨床センターで実施されます。

したがって、EBV診断・治療市場ソリューションの採用に向けて、国のかなりのシフトがあります。インド医学研究評議会（ICMR）によると、中国は2020年4月に50万個の迅速抗体検査キットをインドに送っています。さらに、外国企業の大半が抗CD3抗体を主な対象としているのに対し、中国の研究開発企業は生物学的特異的抗体検査の開発に力を入れています。中国の抗体検査市場は、革新的な生物学的特異抗体の発見と、予想される多くの製品発売イベントにより拡大しています。

目次

第1章 レポート概要

  • 業界の現状分析と成長可能性の展望
  • 調査方法とツール
  • 市場内訳
    • セグメント別
    • 地域別

第2章 市場概要と洞察

  • 調査範囲
  • アナリストの洞察と現在の市場動向
    • 主な調査結果
    • 推奨事項
    • 結論

第3章 競合情勢

  • 主要企業分析
  • Viracta Therapeutics, Inc.
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の動向
  • Atara Biotherapeutics, Inc.
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の動向
  • AlloVir, Inc.
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の動向
  • 主要戦略分析

第4章 市場セグメンテーション

  • 世界のEBV診断・治療市場：診断別
    • ラボベース検査
    • POC検査
  • 世界のEBV診断・治療市場：治療別
    • 抗ウイルス薬（アシクロビル、ガンシクロビル、デシクロビル）
    • その他の薬剤（抗炎症剤、解熱剤、その他）

第5章 地域別分析

  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • イタリア
    • スペイン
    • フランス
    • その他欧州
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他アジア太平洋
  • 世界のその他の地域

第6章 企業プロファイル

  • Advenchen Laboratories LLC
  • Arno Therapeutics Inc.
  • bluebird bio Inc.
  • Cell Medica Ltd.
  • Epiphany Biosciences Inc.
  • Genocea Biosciences Inc.
  • Omeros Corp.
  • TC BioPharm Ltd.
  • Theravectys SA
  • Viracta Therapeutics Inc.
  • Vironika LLC
  • ViroStatics srl
図表

LIST OF TABLES

  • 1. GLOBAL EPSTEIN-BARR VIRUS MARKET RESEARCH AND ANALYSIS, BY DIAGNOSIS, 2022-2030 ($ MILLION)
  • 2. GLOBAL LAB BASED TEST FOR EPSTEIN-BARR VIRUS DIAGNOSIS MARKET RESEARCH AND ANALYSIS BY REGION,2022-2030 ($ MILLION)
  • 3. GLOBAL POC TEST FOR EPSTEIN-BARR VIRUS DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 4. GLOBAL EPSTEIN-BARR VIRUS MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2022-2030 ($ MILLION)
  • 5. GLOBAL ANTIVIRAL DRUGS FOR EPSTEIN-BARR VIRUS TREATMENT MARKET RESEARCH AND ANALYSIS, 2022-2030 ($ MILLION)
  • 6. GLOBAL OTHER DRUGS FOR EPSTEIN-BARR VIRUS TREATMENT MARKET RESEARCH AND ANALYSIS, 2022-2030 ($ MILLION)
  • 7. GLOBAL EPSTEIN-BARR VIRUS DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 8. NORTH AMERICAN EPSTEIN-BARR VIRUS DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 9. NORTH AMERICAN EPSTEIN-BARR VIRUS MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2022-2030 ($ MILLION)
  • 10. NORTH AMERICAN EPSTEIN-BARR VIRUS MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2022-2030 ($ MILLION)
  • 11. EUROPEAN EPSTEIN-BARR VIRUS DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 12. EUROPEAN EPSTEIN-BARR VIRUS MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2022-2030 ($ MILLION)
  • 13. EUROPEAN EPSTEIN-BARR VIRUS MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2022-2030 ($ MILLION)
  • 14. ASIA- PACIFIC EPSTEIN-BARR VIRUS DIAGNOSIS AND TREATMENT RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 15. ASIA- PACIFIC EPSTEIN-BARR VIRUS MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2022-2030 ($ MILLION)
  • 16. ASIA- PACIFIC EPSTEIN-BARR VIRUS MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2022-2030 ($ MILLION)
  • 17. REST OF THE WORLD EPSTEIN-BARR VIRUS DIAGNOSIS AND TREATMENT RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 18. REST OF THE WORLD EPSTEIN-BARR VIRUS MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2022-2030 ($ MILLION)
  • 19. REST OF THE WORLD EPSTEIN-BARR VIRUS MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2022-2030 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL EPSTEIN-BARR VIRUS MARKET SHARE BY DIAGNOSIS, 2022 VS 2030 (%)
  • 2. GLOBAL LAB BASED TEST FOR EPSTEIN-BARR VIRUS DIAGNOSIS MARKETSHARE BY REGION, 2022 VS 2030 (%)
  • 3. GLOBAL POC TEST FOR EPSTEIN-BARR VIRUS DIAGNOSIS AND TREATMENT MARKETSHARE BY REGION, 2022 VS 2030 (%)
  • 4. GLOBAL EPSTEIN-BARR VIRUS MARKETSHARE BY TREATMENT, 2022 VS 2030 (%)
  • 5. GLOBAL ANTIVIRAL DRUGS FOR EPSTEIN-BARR VIRUS DIAGNOSIS AND TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 6. GLOBAL OTHER DRUGS EPSTEIN-BARR VIRUS DIAGNOSIS AND TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 7. GLOBAL EPSTEIN-BARR VIRUS DIAGNOSIS AND TREATMENT MARKETSHARE BY REGION, 2022 VS 2030 (%)
  • 8. US EPSTEIN-BARR VIRUS DIAGNOSIS AND TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 9. CANADA EPSTEIN-BARR VIRUS DIAGNOSIS AND TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 10. UK EPSTEIN-BARR VIRUS DIAGNOSIS AND TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 11. FRANCE EPSTEIN-BARR VIRUS DIAGNOSIS AND TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 12. GERMANY EPSTEIN-BARR VIRUS DIAGNOSIS AND TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 13. ITALY EPSTEIN-BARR VIRUS DIAGNOSIS AND TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 14. SPAIN EPSTEIN-BARR VIRUS DIAGNOSIS AND TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 15. REST OF EUROPE EPSTEIN-BARR VIRUS DIAGNOSIS AND TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 16. INDIA EPSTEIN-BARR VIRUS DIAGNOSIS AND TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 17. CHINA EPSTEIN-BARR VIRUS DIAGNOSIS AND TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 18. JAPAN EPSTEIN-BARR VIRUS DIAGNOSIS AND TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 19. SOUTH KOREA EPSTEIN-BARR VIRUS DIAGNOSIS AND TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 20. REST OF ASIA-PACIFIC EPSTEIN-BARR VIRUS DIAGNOSIS AND TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 21. REST OF THE WORLD EPSTEIN-BARR VIRUS DIAGNOSIS AND TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
目次
Product Code: OMR2027688

Title: Global Epstein - Barr Virus Diagnosis and Treatment Market Size, Share & Trends Analysis Report by Treatment (Lab-Based Test and POC test), by Diagnosis (Antiviral Drugs, and Other Drugs),Forecast Period (2023-2030).

The global Epstein - Barr virus diagnosis and treatment market is anticipated to grow at a considerable CAGR of 5.1% during the forecast period (2023-2030). The considerable prevalence of the Epstein-Barr virus (EBV) is a key factor creating demand for its treatment which in turn driving the global EBV diagnosis and treatment market. The EBV is a herpes virus that normally resides after infection as an organism in the epithelial tissues of the throat and lymphocytes. Most humans carry the virus and blood tests will often show low levels of EBV antibodies. Moreover, Multiple sclerosis (MS) is an incurable autoimmune disease that afflicts 2.8 million people worldwide. People diagnosed with MS experience progressive damage to their central nervous system and can lose about seven years of their life expectancy, according to the National Multiple Sclerosis Society. Researchers at the Harvard T.H. Chan School of Public Health determined that the biggest risk factor for contracting the disease may be previous infection with the Epstein-Barr virus (EBV).

Segmental Outlook

The global Epstein - Barr virus diagnosis and treatment market is segmented on the diagnosis, and treatment. Based on the diagnosis, the market is sub-segmented into lab-based test and POC test. Based on the treatment, the market is sub-segmented into antiviral drugs (Acyclovir, ganciclovir, desciclovir), and other drugs (Anti-inflammatory, Antipyretic and other). Among the diagnosis, the Point of care sub-segment is anticipated to hold a considerable share of the market Point-of-care testing tools have opened up a wide range of options in terms of the indications that can be diagnosed in settings other than a laboratory.

The Antiviral drug Sub-Segment is Anticipated to Hold a Considerable Share of the Global Epstein - Barr virus diagnosis and Treatment Market

Among the treatment, the antiviral test sub-segment is expected to hold a considerable share of the global Epstein - Barr virus diagnosis and Treatment market. Antiviral drugs are the most common drug given in case of infectious diseases and one the major infectious disease The infectious mononucleosis, also called "mono," is a contagious disease. EBV is the most common cause of infectious mononucleosis, but other viruses can also cause this disease. It is common among teenagers and young adults, especially college students. At least one out of four teenagers and young adults who get infected with EBV will develop infectious mononucleosis. A history of infection with EBV known for causing infectious mononucleosis, or mono, and certain types of cancer is believed to be the strongest risk factor for multiple sclerosis (MS).

Regional Outlook

The global Epstein - Barr virus diagnosis and treatment market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America). Among these, North America is anticipated to hold a prominent share of the market across the globe. The increasing autoimmune disease cases and the resulting increase in demand for antibody tests, as well as government initiatives to raise public awareness of the advantages of health insurance programs, are some of the key factors anticipated to propel the regional market growth.

The Asia-Pacific Region is Expected to Grow at a Significant CAGR in the Global Epstein - Barr virus diagnosis and Treatment Market

Among all regions, the Asia-Pacific region is anticipated to grow at a considerable CAGR over the forecast period. Regional growth is attributed to rise number of generic population and increase in number of clinical trials owing to rise in cases of new diseases in the region. In May 2022, The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has launched an early-stage clinical trial to evaluate an investigational preventative vaccine for Epstein-Barr virus (EBV). EBV is the primary cause of infectious mononucleosis ("mono") and is associated with certain cancers and autoimmune diseases. The Phase 1 study is one of only two studies to test an investigational EBV vaccine in more than a decade. It will be conducted at the NIH Clinical Center in Bethesda, Maryland.

Hence, there is considerable shift of the country towards the adoption of the Epstein - Barr virus diagnosis and Treatment market solutions. According to the Indian Council of Medical Research, China sent 500,000 rapid antibody testing kits to India in April 2020. (ICMR). Additionally, Chinese R&D firms are concentrating more on developing bio-specific antibody tests whereas the majority of foreign firms are primarily concerned with anti-CD3 antibodies. The Chinese antibody testing market is expanding due to the discovery of innovative bio-specific antibodies and a number of anticipated product launch events.

Market Players Outlook

The major companies serving the Epstein - Barr virus diagnosis and treatment market include Advenchen Laboratories LLC, Arno Therapeutics Inc, bluebird bio Inc, Cell Medica Ltd, Epiphany Biosciences Inc, and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in March 2023, ModeX Therapeutics and Merck announced the collaboration, which is expected to advance the development of ModeX's MDX-2201, an investigational vaccine targeting the Epstein-Barr virus (EBV). Under the agreement, the two companies will work together to continue the preclinical development of MDX-2201. They also will collaborate to file an investigational new drug (IND) application with the US Food and Drug Administration requesting clearance to test the vaccine candidate for EBV in clinical trials.

The Report Covers:

  • Market value data analysis of 2022 and forecast to 2030.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global Epstein - Barr virus diagnosis and Treatment market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies.
  • Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
  • 3.2. Viracta Therapeutics, Inc.
    • 3.2.1. Overview
    • 3.2.2. Financial Analysis
    • 3.2.3. SWOT Analysis
    • 3.2.4. Recent Developments
  • 3.3. Atara Biotherapeutics, Inc.
    • 3.3.1. Overview
    • 3.3.2. Financial Analysis
    • 3.3.3. SWOT Analysis
    • 3.3.4. Recent Developments
  • 3.4. AlloVir, Inc.
    • 3.4.1. Overview
    • 3.4.2. Financial Analysis
    • 3.4.3. SWOT Analysis
    • 3.4.4. Recent Developments
  • 3.5. Key Strategy Analysis

4. Market Segmentation

  • 4.1. Global Epstein-Barr Virus diagnosis and Treatment Market by Diagnosis
    • 4.1.1. Lab based test
    • 4.1.2. POC Test
  • 4.2. Global Epstein-Barr Virus diagnosis and Treatment Market by Treatment
    • 4.2.1. Antiviral drugs (Acyclovir, ganciclovir, desciclovir)
    • 4.2.2. Other Drugs (Anti-inflammatory, Antipyretic and other)

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. Advenchen Laboratories LLC
  • 6.2. Arno Therapeutics Inc.
  • 6.3. bluebird bio Inc.
  • 6.4. Cell Medica Ltd.
  • 6.5. Epiphany Biosciences Inc.
  • 6.6. Genocea Biosciences Inc.
  • 6.7. Omeros Corp.
  • 6.8. TC BioPharm Ltd.
  • 6.9. Theravectys SA
  • 6.10. Viracta Therapeutics Inc.
  • 6.11. Vironika LLC
  • 6.12. ViroStatics srl